Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Section 4 - Management

References

1. JellingerKA.Post mortem studies in Parkinson's disease–is it possible to detect brain areas for specific symptoms?J Neural Transm Suppl 1999; 56: 1–29.
2. KishSJ, ShannakK, HornykiewiczO.Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876–80.
3. DamierP, HirschEC, AgidY, GraybielAM.The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122: 1437–48.
4. AarslandD, AndersenK, LarsenJP, LolkA, Kragh-SørensenP.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.
5. AarslandD, BrønnickK, LarsenJP, TysnesOB, AlvesG.Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121–6.
6. AarslandD, BrønnickK, Williams-GrayC, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.
7. KulisevskyJ.Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000; 16: 365–79.
8. PagonabarragaJ, KulisevskyJ, LlebariaG, et al. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008; 23: 998–1005.
9. Williams-GrayCH, EvansJR, GorisA, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958–69.
10. AarslandD, AndersenK, LarsenJP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56: 730–6.
11. JanvinCC, LarsenJP, AarslandD, HugdahlK.Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343–9.
12. MuslimovicD, PostB, SpeelmanJD, SchmandB.Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239–45.
13. TaylorAE, Saint-CyrJA.The neuropsychology of Parkinson's disease. Brain Cogn 1995; 28: 281–96.
14. LeesAJ, SmithE.Cognitive deficits in the early stages of Parkinson's disease. Brain 1983; 106: 257–70.
15. EmreM.Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229–37.
16. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
17. LitvanI, AarslandD, AdlerCH, et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814–24.
18. Martinez-HortaS, KulisevskyJ.Is all cognitive impairment in Parkinson's disease “mild cognitive impairment”?J Neural Transm 2011; 118: 1185–90.
19. BrønnickK, AlvesG, AarslandD, TysnesOB, LarsenJP.Verbal memory in drug-naive, newly diagnosed Parkinson's disease: the retrieval deficit hypothesis revisited. Neuropsychology 2011; 25: 114–24.
20. TrösterAI.A précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria. J Int Neuropsychol Soc 2011; 17: 393–406.
21. BowenFP, KamiennyRS, BurnsMM, YahrM.Parkinsonism: effects of levodopa treatment on concept formation. Neurology 1975; 25: 701–4.
22. MorrisRG, DownesJJ, SahakianBJ, et al. Planning and spatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 757–66.
23. OwenAM, JamesM, LeighPN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115: 1727–51.
24. ShohamyD, MyersCE, GeghmanKD, SageJ, GluckMA.L-dopa impairs learning, but spares generalization, in Parkinson's disease. Neuropsychologia 2006; 44: 774–84.
25. BrownRG, MarsdenCD.Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 1990; 13: 21–9.
26. JahanshahiM, JenkinsIH, BrownRG, et al. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain 1995; 118: 913–33.
27. LyooCH, JeongY, RyuYH, RinneJO, LeeMS.Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010; 64: 65–73.
28. HosokaiY, NishioY, HirayamaK, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009; 24: 854–62.
29. BohnenNI, KoeppeRA, MinoshimaS, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848–55.
30. KamagataK, MotoiY, HoriM, et al. Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging 2011; 33: 803–7.
31. SongSK, LeeJE, ParkHJ, et al. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011; 26: 289–96.
32. MelzerTR, WattsR, MacAskillMR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 2011; 134: 845–55.
33. RubergM, RiegerF, VillageoisA, BonnetAM, AgidY.Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 1986; 362: 83–91.
34. KuhlDE, MinoshimaS, FesslerJA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996; 40: 399–410.
35. BohnenNI, KauferDI, IvancoLS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745–8.
36. HilkerR, ThomasAV, KleinJC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716–22.
37. ShimadaH, HiranoS, ShinotohH, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273–8.
38. KleinJC, EggersC, KalbeE, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885–92.
39. PerryEK, CurtisM, DickDJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413–21.
40. WallinA, EkbergS, LindK, et al. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease: a rCBF scintigraphy study. Acta Neurol Scand 2007; 116: 347–54.
41. Seto-SalviaN, ClarimonJ, PagonabarragaJ, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011; 68: 359–64.
42. HallidayGM, McCannH.The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010; 1184: 188–95.
43. AarslandD, MunizG, MatthewsF.Nonlinear decline of mini-mental state examination in Parkinson's disease. Mov Disord 2011; 26: 334–7.
44. TrösterAI, WoodsSP, MorganEE.Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices. Arch Clin Neuropsychol 2007; 22: 711–8.
45. FoltynieT, GoldbergTE, LewisSG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004; 19: 885–91.
46. BohnenNI, AlbinRL.The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564–73.
47. CalabresiP, PicconiB, ParnettiL, Di FilippoM.A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006; 5: 974–83.
48. EmreM, AarslandD, AlbaneseA, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.
49. WilliamsGV, CastnerSA.Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 2006; 139: 263–76.
50. CohenJD, PerlsteinWM, BraverTS, et al. Temporal dynamics of brain activation during a working memory task. Nature 1997; 386: 604–8.
51. CastnerSA, Goldman-RakicPS.Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 2004; 24: 1446–50.
52. GaoWJ, Goldman-RakicPS.Selective modulation of excitatory and inhibitory microcircuits by dopamine. Proc Natl Acad Sci U S A 2003; 100: 2836–41.
53. Goldman-RakicPS, CastnerSA, SvenssonTH, SieverLJ, WilliamsGV.Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004; 174: 3–16.
54. MizoguchiK, YuzuriharaM, IshigeA, et al. Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J Neurosci 2000; 20: 1568–74.
55. BackmanL, KarlssonS, FischerH, et al. Dopamine D(1) receptors and age differences in brain activation during working memory. Neurobiol Aging 2011; 32: 1849–56.
56. CallicottJH, MattayVS, BertolinoA, et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 1999; 9: 20–6.
57. WilliamsGV, Goldman-RakicPS.Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572–5.
58. KimbergDY, D'EspositoM, FarahMJ.Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 1997; 8: 3581–5.
59. VijayraghavanS, WangM, BirnbaumSG, WilliamsGV, ArnstenAF.Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007; 10: 376–84.
60. KulisevskyJ, Pascual-SedanoB, BarbanojM, et al. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 2007; 22: 62–7.
61. DamierP, HirschEC, AgidY, GraybielAM.The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999; 122: 1421–36.
62. JellingerKA.The pathology of Parkinson's disease. Adv Neurol 2001; 86: 55–72.
63. CropleyVL, FujitaM, InnisRB, NathanPJ.Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 2006; 59: 898–907.
64. DreherJC, GuigonE, BurnodY.A model of prefrontal cortex dopaminergic modulation during the delayed alternation task. J Cogn Neurosci 2002; 14: 853–65.
65. El-GhundiM, O'DowdBF, GeorgeSR.Insights into the role of dopamine receptor systems in learning and memory. Rev Neurosci 2007; 18: 37–66.
66. MonchiO, PetridesM, DoyonJ, et al. Neural bases of set-shifting deficits in Parkinson's disease. J Neurosci 2004; 24: 702–10.
67. GothamAM, BrownRG, MarsdenCD.Frontal’ cognitive function in patients with Parkinson's disease ‘on’ and ‘off’ levodopa. Brain 1988; 111: 299–321.
68. KulisevskyJ, AvilaA, BarbanojM, et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996; 119: 2121–32.
69. SwainsonR, RogersRD, SahakianBJ, et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000; 38: 596–612.
70. GrossmanM, GlosserG, KalmansonJ, et al. Dopamine supports sentence comprehension in Parkinson's disease. J Neurol Sci 2001; 184: 123–30.
71. CoolsR, BarkerRA, SahakianBJ, RobbinsTW.Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001; 11: 1136–43.
72. CoolsR, BarkerRA, SahakianBJ, RobbinsTW.L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003; 41: 1431–41.
73. MacDonaldPA, MacDonaldAA, SeergobinKN, et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 2011; 134: 1447–63.
74. de la Fuente-FernandezR, SossiV, HuangZ, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747–54.
75. FoltynieT, CheeranB, Williams-GrayCH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 141–4.
76. HooglandJ, de BieRM, Williams-GrayCH, et al. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010; 25: 2550–4.
77. Pascual-SedanoB, KulisevskyJ, BarbanojM, et al. Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc 2008; 14: 832–41.
78. BraakH, GhebremedhinE, RubU, BratzkeH, Del TrediciK.Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121–34.
79. BalleineBW, O'DohertyJP.Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010; 35: 48–69.
80. SchultzW.Getting formal with dopamine and reward. Neuron 2002; 36: 241–63.
81. RobbinsTW, EverittBJ.Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 1996; 6: 228–36.
82. BerridgeKC.The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191: 391–431.
83. WhiteNM.Some highlights of research on the effects of caudate nucleus lesions over the past 200 years. Behav Brain Res 2009; 199: 3–23.
84. AtallahHE, Lopez-PaniaguaD, RudyJW, O'ReillyRC.Separate neural substrates for skill learning and performance in the ventral and dorsal striatum. Nat Neurosci 2007; 10: 126–31.
85. MuhlbergerA, WieserMJ, GerdesAB, et al. Stop looking angry and smile, please: start and stop of the very same facial expression differentially activate threat- and reward-related brain networks. Soc Cogn Affect Neurosci 2011; 6: 321–9.
86. MacdonaldPA, MonchiO.Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis 2011; 2011: 572743.
87. SchultzW.Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. Curr Opin Neurobiol 2004; 14: 139–47.
88. DagherA, RobbinsTW.Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009; 61: 502–10.
89. CamaraE, Rodriguez-FornellsA, MunteTF.Microstructural brain differences predict functional hemodynamic responses in a reward processing task. J Neurosci 2010; 30: 11398–402.
90. CostaVD, LangPJ, SabatinelliD, VersaceF, BradleyMM.Emotional imagery: assessing pleasure and arousal in the brain's reward circuitry. Hum Brain Mapp 2010; 31: 1446–57.
91. GrahnJA, ParkinsonJA, OwenAM.The cognitive functions of the caudate nucleus. Prog Neurobiol 2008; 86: 141–55.
92. KulisevskyJ, García-SánchezC, BerthierML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000; 15: 613–26.
93. CostaA, PeppeA, Dell'AgnelloG, CaltagironeC, CarlesimoGA.Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 2009; 47: 1374–81.
94. ShookSK, FranzEA, HigginsonCI, WheelockVL, SigvardtKA.Dopamine dependency of cognitive switching and response repetition effects in Parkinson's patients. Neuropsychologia 2005; 43: 1990–9.
95. LewisSJ, SlaboszA, RobbinsTW, BarkerRA, OwenAM.Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005; 43: 823–32.
96. TremblayPL, BedardMA, LangloisD, et al. Movement chunking during sequence learning is a dopamine-dependent process: a study conducted in Parkinson's disease. Exp Brain Res 2010; 205: 375–85.
97. Hanna-PladdyB, HeilmanKM.Dopaminergic modulation of the planning phase of skill acquisition in Parkinson's disease. Neurocase 2010; 16: 182–90.
98. CoolsR, BarkerRA, SahakianBJ, RobbinsTW.Mechanisms of cognitive set flexibility in Parkinson's disease. Brain 2001; 124: 2503–12.
99. SohnMH, UrsuS, AndersonJR, StengerVA, CarterCS.The role of prefrontal cortex and posterior parietal cortex in task switching. Proc Natl Acad Sci U S A 2000; 97: 13448–53.
100. MollionH, Ventre-DomineyJ, DomineyPF, BroussolleE.Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease. Neuropsychologia 2003; 41: 1442–51.
101. LangeKW, RobbinsTW, MarsdenCD, et al. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992; 107: 394–404.
102. SlaboszA, LewisSJ, SmigasiewiczK, et al. The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease. Neuropsychology 2006; 20: 578–88.
103. CostaA, PeppeA, BrusaL, et al. Dopaminergic modulation of prospective memory in Parkinson's disease. Behav Neurol 2008; 19: 45–8.
104. Nagano-SaitoA, LiuJ, DoyonJ, DagherA.Dopamine modulates default mode network deactivation in elderly individuals during the Tower of London task. Neurosci Lett 2009; 458: 1–5.
105. van der MeerMA, RedishAD.Ventral striatum: a critical look at models of learning and evaluation. Curr Opin Neurobiol 2011; 21: 387–92.
106. JahanshahiM, WilkinsonL, GahirH, DharmindaA, LagnadoDA.Medication impairs probabilistic classification learning in Parkinson's disease. Neuropsychologia 2010; 48: 1096–103.
107. FrankMJ, SeebergerLC, O'ReillyRC.By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004; 306: 1940–3.
108. SeoM, BeigiM, JahanshahiM, AverbeckBB.Effects of dopamine medication on sequence learning with stochastic feedback in Parkinson's disease. Front Syst Neurosci 2010; 4: 36.
109. FeiginA, GhilardiMF, CarbonM, et al. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 2003; 60: 1744–9.
110. GhilardiMF, FeiginAS, BattagliaF, et al. L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 146–51.
111. TomerR, Aharon-PeretzJ, TsitrinbaumZ.Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease. Neuropsychologia 2007; 45: 357–67.
112. CoolsR, ClarkL, OwenAM, RobbinsTW.Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci 2002; 22: 4563–7.
113. GraefS, BieleG, KrugelLK, et al. Differential influence of levodopa on reward-based learning in Parkinson's disease. Front Hum Neurosci 2010; 4: 169.
114. Williams-GrayCH, HampshireA, BarkerRA, OwenAM.Attentional control in Parkinson's disease is dependent on COMT val158met genotype. Brain 2008; 131: 397–408.
115. CheesmanAL, BarkerRA, LewisSJ, et al. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1204–10.
116. KatzenHL, LevinBE, WeinerW.Side and type of motor symptom influence cognition in Parkinson's disease. Mov Disord 2006; 21: 1947–53.
117. HoltgravesT, McNamaraP, CappaertK, DursoR.Linguistic correlates of asymmetric motor symptom severity in Parkinson's disease. Brain Cogn 2010; 72: 189–96.
118. WitjasT, KaphanE, AzulayJP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.
119. NuttJG.On–off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987; 22: 535–40.
120. ZappiaM, OliveriRL, MontesantiR, et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 1999; 52: 763–7.
121. PoeweW, BergerW, BenkeT, ScheloskyL.High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991; 29: 670–3.
122. HuangC, MattisP, PerrineK, et al. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008; 70: 1470–7.
123. WiseRA.Dopamine, learning and motivation. Nat Rev Neurosci 2004; 5: 483–94.
124. SchultzW, DayanP, MontaguePR.A neural substrate of prediction and reward. Science 1997; 275: 1593–9.
125. O'DohertyJP, DayanP, FristonK, CritchleyH, DolanRJ.Temporal difference models and reward-related learning in the human brain. Neuron 2003; 38: 329–37.
126. PessiglioneM, SeymourB, FlandinG, DolanRJ, FrithCD.Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006; 442: 1042–5.
127. JochamG, KleinTA, UllspergerM.Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices. J Neurosci 2011; 31: 1606–13.
128. O'SullivanSS, WuK, PolitisM, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011; 134: 969–78.
129. LawrenceAD, EvansAH, LeesAJ.Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?Lancet Neurol 2003; 2: 595–604.
130. van EimerenT, BallangerB, PellecchiaG, et al. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?Neuropsychopharmacology 2009; 34: 2758–66.
131. WeintraubD, KoesterJ, PotenzaMN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.
132. WyvellCL, BerridgeKC.Incentive sensitization by previous amphetamine exposure: increased cue-triggered “wanting” for sucrose reward. J Neurosci 2001; 21: 7831–40.
133. VoonV, PessiglioneM, BrezingC, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010; 65: 135–42.
134. EvansAH, LawrenceAD, CresswellSA, KatzenschlagerR, LeesAJ.Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord 2010; 25: 867–76.
135. RabinakCA, NirenbergMJ.Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58–63.
136. ThoboisS, ArdouinC, LhomméeE, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–27.
137. PapapetropoulosS, MashDC.Psychotic symptoms in Parkinson's disease: from description to etiology. J Neurol 2005; 252: 753–64.
138. FénelonG, MahieuxF, HuonR, ZieglerM.Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733–45.
139. LlebariaG, PagonabarragaJ, Martinez-CorralM, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord 2010; 25: 2785–91.
140. FénelonG, AlvesG.Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289: 12–17.
141. KulisevskyJ, RoldanE.Hallucinations and sleep disturbances in Parkinson's disease. Neurology 2004; 63 (8 Suppl 3): S28–30.
142. KulisevskyJ, PagonabarragaJ, Pascual-SedanoB, García-SánchezC, GironellA.Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008; 23: 1889–96.
143. AarslandD, BrønnickK, EhrtU, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36–42.
144. WilliamsDR, LeesAJ.Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–10.
145. ForsaaEB, LarsenJP, Wentzel-LarsenT, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996–1001.
146. GoetzCG, LeurgansS, PappertEJ, RamanR, StemerAB.Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001; 57: 2078–82.
147. GoetzCG, WuuJ, CurgianL, LeurgansS.Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 2006; 21: 267–70.
148. HolroydS, CurrieL, WootenGF.Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734–8.
149. WeintraubD, MoralesKH, DudaJE, MobergPJ, SternMB.Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. Parkinsonism Relat Disord 2006; 12: 427–31.
150. GoetzCG, PappertEJ, BlasucciLM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50: 515–17.
151. AarslandD, LarsenJP, CumminsJL, LaakeK.Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595–601.
152. BiousseV, SkibellBC, WattsRL, et al. Ophthalmologic features of Parkinson's disease. Neurology 2004; 62: 177–80.
153. BiglanKM, HollowayRG, McDermottMP, RichardIH.Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69: 187–95.
154. ZahodneLB, FernandezHH.Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008; 25: 665–82.
155. GoldmanJG.New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis 2011; 2011: 675630.
156. GoetzCG, FanW, LeurgansS, BernardB, StebbinsGT.The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol 2006; 63: 713–16.
157. TrifiroG, SpinaE, GambassiG.Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?Pharmacol Res 2009; 59: 1–12.
158. SeppiK, WeintraubD, CoelhoM, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3): S42–80.
159. OndoWG, TintnerR, VoungKD, LaiD, RingholzG.Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958–63.
160. ShotboltP, SamuelM, FoxC, DavidAS.A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009; 5: 327–32.
161. MaidmentI, FoxC, BoustaniM. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006; (1): CD004747.
162. FoxC, RichardsonK, MaidmentID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council cognitive function and ageing study. J Am Geriatr Soc 2011; 59: 1477–83.
163. OguruM, TachibanaH, TodaK, OkudaB, OkaN.Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23: 35–41.
164. PluckGC, BrownRG.Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636–42.
165. PedersenKF, LarsenJP, AlvesG, AarslandD.Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism Relat Disord 2009; 15: 295–9.
166. Kirsch-DarrowL, FernandezHH, MarsiskeM, OkunMS, BowersD.Dissociating apathy and depression in Parkinson disease. Neurology 2006; 67: 33–8.
167. Martinez-CorralM, PagonabarragaJ, LlebariaG, et al. Facial emotion recognition impairment in patients with Parkinson's disease and isolated apathy. Parkinsons Dis 2010; 2010: 930627.
168. RichardIH.Apathy does not equal depression in Parkinson disease: why we should care. Neurology 2006; 67: 10–11.
169. StarksteinSE, MaybergHS, PreziosiTJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134–9.
170. ReijndersJS, EhrtU, WeberWE, AarslandD, LeentjensAF.A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183–9.
171. DujardinK, SockeelP, DevosD, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007; 22: 778–84.
172. StarksteinSE.Apathy in Parkinson's disease: diagnostic and etiological dilemmas. Mov Disord 2012; 27: 174–8.
173. Kirsch-DarrowL, ZahodneLB, MarsiskeM, et al. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 182–8.
174. Le JeuneF, DrapierD, BourguignonA, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746–51.
175. SchragA, JahanshahiM, QuinnN.What contributes to quality of life in patients with Parkinson's disease?J Neurol Neurosurg Psychiatry 2000; 69: 308–12.
176. MenzaM, DobkinRD, MarinH, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 2009; 24: 1325–32.
177. RemyP, DoderM, LeesA, TurjanskiN, BrooksD.Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314–22.
178. BaroneP.Treatment of depressive symptoms in Parkinson's disease. Eur J Neurol 2011; 18 (Suppl 1): 11–15.
179. DevosD, DujardinK, PoirotI, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23: 850–7.
180. MenzaM, DobkinRD, MarinH, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886–92.
181. PalE, NagyF, AschermannZ, BalazsE, KovacsN.The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010; 25: 2311–7.
182. da SilvaTM, MunhozRP, AlvarezC, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008; 111: 351–9.
183. WeintraubD, MavandadiS, MamikonyanE, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448–55.
184. BaroneP, PoeweW, AlbrechtS, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–80.
185. BaroneP, ScarzellaL, MarconiR, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601–7.
186. DissanayakaNN, SellbachA, MathesonS, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010; 25: 838–45.
187. LeentjensAF, DujardinK, MarshL, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 2015–25.
188. ShibaM, BowerJH, MaraganoreDM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000; 15: 669–77.
189. PontoneGM, WilliamsJR, AndersonKE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24: 1333–8.
190. MondoloF, JahanshahiM, GranaA, et al. Evaluation of anxiety in Parkinson's disease with some commonly used rating scales. Neurol Sci 2007; 28: 270–5.
191. MaricleRA, NuttJG, ValentineRJ, CarterJH.Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995; 45: 1757–60.
192. Eskow JaunarajsKL, Angoa-PerezM, KuhnDM, BishopC.Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev 2011; 35: 556–64.
193. WeintraubD, BurnDJ.Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26: 1022–31.
194. WeintraubD, SternMB.Intervening in the neuropsychiatric features of Parkinson's disease. Expert Rev Neurother 2007; 7: 699–710.
195. MamikonyanE, SiderowfAD, DudaJE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008; 23: 75–80.
196. VoonV, FernagutPO, WickensJ, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140–9.
197. EvansAH, StrafellaAP, WeintraubD, StacyM.Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; 24: 1561–70.
198. EvansAH, KatzenschlagerR, PaviourD, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397–405.
199. KulisevskyJ, PagonabarragaJ, Martinez-CorralM.Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity. J Neurol 2009; 256: 816–9.
200. Driver-DunckleyE, SamantaJ, StacyM.Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61: 422–3.
201. MolinaJA, Sainz-ArtigaMJ, FraileA, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?Mov Disord 2000; 15: 869–72.
202. SmedingHM, GoudriaanAE, FonckeEM, et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78: 517–19.
203. LimSY, O'SullivanSS, KotschetK, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148–52.
204. LeeJY, KimJM, KimJW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010; 16: 202–7.
205. FernandezHH, FriedmanJH.Punding on L-dopa. Mov Disord 1999; 14: 836–8.
206. BearnJ, EvansA, KelleherM, TurnerK, LeesA.Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 2004; 76: 305–10.
207. GiovannoniG, O'SullivanJD, TurnerK, MansonAJ, LeesAJ.Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–8.
208. Pascual-SedanoB, García-SánchezC, CampolongoA, PagonabarragaJ, KulisevskyJ.Walkabout’: An unrecognized compulsive behavior in Parkinson's disease. Mov Disord 2010; 25 (Suppl 2): S284.
209. VoonV, MehtaAR, HallettM.Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 2011; 24: 324–30.
210. LyonsKE, FriedmanJH, HermanowiczN, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 2010; 33: 5–10.
211. ThomasA, BonanniL, GambiF, Di IorioA, OnofrjM.Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68: 400–4.
212. WeintraubD, SohrM, PotenzaMN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010; 68: 963–8.
213. CeravoloR, FrosiniD, RossiC, BonuccelliU.Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. J Neurol 2010; 257 (Suppl 2): S276–83.
214. ThoboisS, ArdouinC, LhomméeE, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–27.
215. ArdouinC, VoonV, WorbeY, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21: 1941–6.
216. BroenM, DuitsA, Visser-VandewalleV, TemelY, WinogrodzkaA.Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011; 17: 413–17.

References

1. MoroE, LozanoAM, PollakP, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010; 25: 578–86.
2. FollettKA, WeaverFM, SternM, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077–91.
3. DeuschlG, Schade-BrittingerC, KrackP, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908.
4. WeaverFM, FollettK, SternM, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63–73.
5. WilliamsA, GillS, VarmaT, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9: 581–91.
6. OkunMS, GalloBV, MandyburG, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol 2012; 11: 140–9.
7. TemelY, Visser-VandewalleV, AendekerkB, et al. Acute and separate modulation of motor and cognitive performance in parkinsonian rats by bilateral stimulation of the subthalamic nucleus. Exp Neurol 2005; 193: 43–52.
8. HamaniC, Saint-CyrJA, FraserJ, KaplittM, LozanoAM.The subthalamic nucleus in the context of movement disorders. Brain 2004; 127: 4–20.
9. FrankMJ, SamantaJ, MoustafaAA, ShermanSJ.Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007; 318: 1309–12.
10. ParentA, HazratiLN.Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 1995; 20: 128–54.
11. AgidY.[Mechanism of cell death in neurodegenerative disorders: apropos of Parkinson disease]. C R Seances Soc Biol Fil 1993; 187: 37–46.
12. KishSJ, ShannakK, HornykiewiczO.Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876–80.
13. CoolsR, BarkerRA, SahakianBJ, RobbinsTW.L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003; 41: 1431–41.
14. VolkmannJ, DanielsC, WittK.Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010; 6: 487–98.
15. BejjaniBP, ArnulfI, DemeretS, et al. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?Ann Neurol 2000; 47: 655–8.
16. KulisevskyJ, BerthierML, GironellA, et al. Mania following deep brain stimulation for Parkinson's disease. Neurology 2002; 59: 1421–4.
17. MalletL, SchüpbachM, N'DiayeK, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A 2007; 104: 10661–6.
18. Raucher-CheneD, CharrelCL, de MaindrevilleAD, LimosinF.Manic episode with psychotic symptoms in a patient with Parkinson's disease treated by subthalamic nucleus stimulation: improvement on switching the target. J Neurol Sci 2008; 273: 116–17.
19. MandatTS, HurwitzT, HoneyCR.Hypomania as an adverse effect of subthalamic nucleus stimulation: report of two cases. Acta Neurochir (Wien) 2006; 148: 895–7.
20. HerzogJ, ReiffJ, KrackP, et al. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease. Mov Disord 2003; 18: 1382–4.
21. UllaM, ThoboisS, LlorcaPM, et al. Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study. J Neurol Neurosurg Psychiatry 2011; 82: 607–14.
22. BerneyA, VingerhoetsF, PerrinA, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002; 59: 1427–9.
23. HouetoJL, MesnageV, MalletL, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701–7.
24. TommasiG, LanotteM, AlbertU, et al. Transient acute depressive state induced by subthalamic region stimulation. J Neurol Sci 2008; 273: 135–8.
25. BejjaniBP, DamierP, ArnulfI, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340: 1476–80.
26. OkunMS, FernandezHH, WuSS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65: 586–95.
27. VoonV, KubuC, KrackP, HouetoJL, TrösterAI.Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 (Suppl 14): S305–27.
28. TemelY, BoothmanLJ, BloklandA, et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci U S A 2007; 104: 17087–92.
29. WittK, DanielsC, ReiffJ, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7: 605–14.
30. MenzaM, DobkinRD, MarinH, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886–92.
31. CastelliL, ZibettiM, RizziL, et al. Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study. J Neurol 2008; 255: 1515–20.
32. SchüpbachWM, ChastanN, WelterML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1640–4.
33. KrackP, BatirA, Van BlercomN, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925–34.
34. KaiserI, Kryspin-ExnerI, BruckeT, VolcD, AleschF.Long-term effects of STN DBS on mood: psychosocial profiles remain stable in a 3-year follow-up. BMC Neurol 2008; 8: 43.
35. VolkmannJ, AllertN, VogesJ, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001; 56(4): 548–51.
36. AndersonVC, BurchielKJ, HogarthP, FavreJ, HammerstadJP.Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005; 62: 554–60.
37. BerneyA, PanissetM, SadikotAF, et al. Mood stability during acute stimulator challenge in Parkinson's disease patients under long-term treatment with subthalamic deep brain stimulation. Mov Disord 2007; 22: 1093–6.
38. Saint-CyrJA, TrepanierLL, KumarR, LozanoAM, LangAE.Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000; 123: 2091–108.
39. FunkiewiezA, ArdouinC, KrackP, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524–30.
40. DrapierD, DrapierS, SauleauP, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?J Neurol 2006; 253: 1083–91.
41. CzerneckiV, SchüpbachM, YaiciS, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008; 23: 964–9.
42. TrösterAI.Neuropsychology of deep brain stimulation in neurology and psychiatry. Front Biosci 2009; 14: 1857–79.
43. FunkiewiezA, ArdouinC, CaputoE, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834–9.
44. ThoboisS, ArdouinC, LhomméeE, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–27.
45. ChatterjeeA, FahnS.Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14: 461–2.
46. MarinRS, FogelBS, HawkinsJ, DuffyJ, KruppB.Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995; 7: 23–30.
47. PluckGC, BrownRG.Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636–42.
48. TemelY, TanS, VlamingsR, et al. Cognitive and limbic effects of deep brain stimulation in preclinical studies. Front Biosci 2009; 14: 1891–901.
49. Le JeuneF, DrapierD, BourguignonA, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746–51.
50. CzerneckiV, PillonB, HouetoJL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?J Neurol Neurosurg Psychiatry 2005; 76: 775–9.
51. HouetoJL, MalletL, MesnageV, et al. Subthalamic stimulation in Parkinson disease: behavior and social adaptation. Arch Neurol 2006; 63: 1090–5.
52. DanieleA, AlbaneseA, ContarinoMF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 175–82.
53. BiseulI, SauleauP, HaegelenC, et al. Fear recognition is impaired by subthalamic nucleus stimulation in Parkinson's disease. Neuropsychologia 2005; 43: 1054–9.
54. VicenteS, BiseulI, PeronJ, et al. Subthalamic nucleus stimulation affects subjective emotional experience in Parkinson's disease patients. Neuropsychologia 2009; 47: 1928–37.
55. SensiM, EleopraR, CavalloMA, et al. Explosive-aggressive behavior related to bilateral subthalamic stimulation. Parkinsonism Relat Disord 2004; 10: 247–51.
56. BejjaniBP, HouetoJL, HarizM, et al. Aggressive behavior induced by intraoperative stimulation in the triangle of Sano. Neurology 2002; 59: 1425–7.
57. BurdickAP, FooteKD, WuS, et al. Do patients get angrier following STN, GPi, and thalamic deep brain stimulation. Neuroimage 2011; 54 (Suppl 1): S227–32.
58. RomitoLM, RajaM, DanieleA, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002; 17: 1371–4.
59. DoshiP, BhargavaP.Hypersexuality following subthalamic nucleus stimulation for Parkinson's disease. Neurol India 2008; 56: 474–6.
60. MachadoAG, HiremathGK, SalazarF, RezaiAR.Fracture of subthalamic nucleus deep brain stimulation hardware as a result of compulsive manipulation: case report. Neurosurgery 2005; 57: E1318.
61. SmedingHM, GoudriaanAE, FonckeEM, et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78: 517–19.
62. HalbigTD, TseW, FrisinaPG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009; 16: 493–7.
63. BaupN, GrabliD, KarachiC, et al. High-frequency stimulation of the anterior subthalamic nucleus reduces stereotyped behaviors in primates. J Neurosci 2008; 28: 8785–8.
64. GreenbergBD, MaloneDA, FriehsGM, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31: 2384–93.
65. FontaineD, MatteiV, BorgM, et al. Effect of subthalamic nucleus stimulation on obsessive-compulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg 2004; 100: 1084–6.
66. MalletL, MesnageV, HouetoJL, et al. Compulsions, Parkinson's disease, and stimulation. Lancet 2002; 360: 1302–4.
67. MalletL, PolosanM, JaafariN, et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008; 359: 2121–34.
68. SchüpbachM, GargiuloM, WelterML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body?Neurology 2006; 66: 1811–16.
69. WeintraubD, KoesterJ, PotenzaMN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.
70. WeintraubD.Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. Parkinsonism Relat Disord 2009; 15 (Suppl 3): S110–3.
71. BroenM, DuitsA, Visser-VandewalleV, TemelY, WinogrodzkaA.Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011; 17: 413–17.
72. DemetriadesP, RickardsH, CavannaAE.Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinsons Dis 2011; 2011: 658415.
73. Rodriguez-OrozMC, Lopez-AzcarateJ, Garcia-GarciaD, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2011; 134: 36–49.
74. WylieSA, RidderinkhofKR, EliasWJ, et al. Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain 2010; 133: 3611–24.
75. MolinaJA, Sainz-ArtigaMJ, FraileA, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?Mov Disord 2000; 15: 869–72.
76. SeedatS, KeslerS, NiehausDJ, SteinDJ.Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000; 11: 185–6.
77. BandiniF, PrimaveraA, PizzornoM, CocitoL.Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 369–71.
78. WitjasT, BaunezC, HenryJM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005; 20: 1052–5.
79. ArdouinC, VoonV, WorbeY, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21: 1941–6.
80. LimSY, O'SullivanSS, KotschetK, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148–52.
81. KnobelD, AybekS, PolloC, VingerhoetsFJ, BerneyA.Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol 2008; 21: 187–9.
82. ZahodneLB, SusatiaF, BowersD, et al. Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. J Neuropsychiatry Clin Neurosci 2011; 23: 56–62.
83. LockeMC, WuSS, FooteKD, et al. Weight changes in subthalamic nucleus vs globus pallidus internus deep brain stimulation: results from the COMPARE Parkinson disease deep brain stimulation cohort. Neurosurgery 2011; 68: 1233–7.
84. PallantiS, BernardiS, RaglioneLM, et al. Complex repetitive behavior: punding after bilateral subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 376–80.
85. EvansAH, KatzenschlagerR, PaviourD, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397–405.
86. MiyasakiJM, Al HassanK, LangAE, VoonV.Punding prevalence in Parkinson's disease. Mov Disord 2007; 22: 1179–81.
87. SoulasT, GurruchagaJM, PalfiS, et al. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2008; 79: 952–4.
88. VoonV, KrackP, LangAE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131: 2720–8.
89. MyslobodskyM, LalondeFM, HicksL.Are patients with Parkinson's disease suicidal?J Geriatr Psychiatry Neurol 2001; 14: 120–4.
90. RodriguesAM, RosasMJ, GagoMF, et al. Suicide attempts after subthalamic nucleus stimulation for Parkinson's disease. Eur Neurol 2010; 63: 176–9.
91. FrankMJ, SeebergerLC, O'ReillyRC.By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004; 306: 1940–3.
92. UmemuraA, OkaY, OkitaK, MatsukawaN, YamadaK.Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions. J Neurosurg 2011; 114: 1701–5.
93. KempsterPA, WilliamsDR, SelikhovaM, et al. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007; 130: 2123–8.

References

1. AarslandD, MarshL, SchragA.Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; 24: 2175–86.
2. AarslandD, LarsenJP, KarlsenK, LimNG, TandbergE.Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866–74.
3. AarslandD, LarsenJP, TandbergE, LaakeK.Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938–42.
4. SchneiderLS, DagermanKS, InselP.Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43.
5. FénelonG, MahieuxF, HulonR, ZiéglerM.Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 2000; 123: 733–45.
6. MiyasakiJM, ShannonK, VoonV, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996–1002.
7. TroschRM, FriedmanJH, LannonMC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13: 377–82.
8. BennettJP, LandowER, DietrichS, SchuhLA.Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994; 9: 409–14.
9. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–63.
10. ShotboltP, SamuelM, DavidA.Quetiapine in the treatment of psychosis in Parkinson's disease. Ther Adv Neurol Disord 2010; 3: 339–50.
11. EngML, WeltyTE.Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother 2010; 8: 316–30.
12. FriedmanJH.Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010; 16: 553–60.
13. MeltzerHY, MillsR, RevellS, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010; 35: 881–92.
14. EmreM, AarslandD, AlbaneseA, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.
15. BurnD, EmreM, McKeithI, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899–907.
16. ZoldanJ, FriedbergG, LivnehM, MelamedE.Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305–8.
17. FénelonG.Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 2008; 13 (3 Suppl 4): 18–25.
18. DiederichNJ, FénelonG, StebbinsG, GoetzCG.Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 5: 331–42.
19. DotchinCL, JusabaniA, WalkerRW.Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat Disord 2009; 15: 457–60.
20. GoetzCG, PappertEJ, BlasucciLM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50: 515–17.
21. GoetzCG, FanW, LeurgansS, BernardB, StebbinsGT.The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol 2006; 63: 713–16.
22. RavinaB, MarderK, FernandezHH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS/ NIMH work group. Mov Disord 2007; 22: 1061–8.
23. FénelonG, SoulasT, ZenasniF, Cleret de LangavantL.The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010; 25: 763–6.
24. TomlinsonCL, StoweR, PatelS, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649–53.
25. BrønnickK, EmreM, TekinS, HaugenSB, AarslandD.Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2011; 26: 824–9.
26. GoetzCG.Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl 3): S38–41.
27. CummingsJL, ZhongK.Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat Rev Drug Discov 2006; 5: 64–74.
28. WoltersEC, HurwitzTA, MakE, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832–4.
29. ClarkWS, StreetJS, FeldmanPD, BreierA.The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 2001; 62: 34–40.
30. FernandezHH, AarslandD, FénelonG, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 484–500.
31. OlanowCW, RascolO, HauserR, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.
32. HanagasiHA, GurvitH, UnsalanP, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011; 26: 1851–8.
33. BraakH, RübU, Del TrediciK.Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006; 248: 255–8.
34. TariotPN, CummingsJL, KatzIR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–9.
35. CummingsJL, SchneiderL, TariotPN, KershawPR, YuanW.Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161: 532–8.
36. WuY, LeW, JankovicJ.Preclinical biomarkers of Parkinson disease. Arch Neurol 2011; 68: 22–30.
37. ScherflerC, SchwarzJ, AntoniniA, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229–38.
38. TangCC, EidelbergD.Abnormal metabolic brain networks in Parkinson's disease from blackboard to bedside. Prog Brain Res 2010; 184: 161–76.